THE IMPORTANCE OF PRIMARY BARRIERS
This was highlighted in macaque studies, which showed how estrogen treatment protected animals from infection [2] , and progesterone treatment enhanced an animal's susceptibility to infection [2] . However, the possible modulation of leukocytes by sex hormones within these tissues [1] , which might also impact infection, could contribute. In the female reproductive tract, the virus must not only pass the epithelial layer but also overcome acidic pH, cervically secreted mucous, hydrogen peroxide, and potentially, other innate defenses secreted at the mucosa (see review in ref. [3] ). This barrage of mechanisms is quite effective when observing transmission in vivo, as there are infrequent populations that are infected at the cervicovaginal mucosa. Such observations have led to the hypothesis that small, founder populations of infected cells are key for initial dissemination [4] . The idea of a transmission bottleneck is supported further by the observations of early, replicating variants in humans being monophyletic [5] and thus, suggestive that few virions reach the point of a productive infection. Although one must note that the rectal mucosa consisting only of a monolayered epithelium is more prone to lesions, which might make it even more susceptible for HIV/SIV transmission. In terms of early defense mechanism, the rectal milieu may contain hydrogen peroxide, but the pH is rather neutral. This makes it much easier for the virus to survive and to cross the barrier and reach the L. propria. The mechanism(s) that allow the small proportion of virus to survive, clearly following vaginal or rectal exposure, warrants further study.
DEFINING THE CELLULAR SUBSTRATES
Breaking down cellular partners of HIV as "cellular substrates" will make it easier to address the actions of microbicides later. Recently, observations of predominant L. propria CD4 ϩ T cell infection in vivo have led to the hypothesis that permissive leukocyte abundance dictates viral transmission [6] . Shortcomings with this hypothesis are the lack of consideration of less-abundant, permissive cells, in addition to cells that bind and traffic virus, independent of their infection. In addition, in vivo observations of transmission often involve high levels of viral inoculum and therefore, may or may not be representative of potentially lower inocula in seminal fluid.
Virus binding and transfer independent of infection: potential passive substrates (Fig. 1A) Epithelial cells (ECs) are the first cells encountering virus and/or infected cells. ECs may not be productively infected by HIV in vitro [4, 7] , but ECs can endocytose and transfer virus to CD4 ϩ T cells [8] . Fibronectin, present in seminal plasma, might also facilitate ␤-integrin interaction of virus with ECs [7, 9] , in addition to viral capture by surface heparan sulfates [10] .
DC are located within and just underneath the epithelial layers, thereby positioning them as one of the first leukocyte substrates. To sample pathogens/antigens, Langerhans cells (LCs) in the outer epithelia and DCs within the L. propria [11] may reach their dendrites to the epithelial surfaces. Considering how ECs and DC influence each other and how they interact with HIV will be important to appreciate these early events in HIV transmission. Immature and mature DC bind and internalize virus efficiently in vitro [12] and rapidly transfer captured virus to CD4 ϩ T cells across the "virologic synapse" [13] [14] [15] . The relative efficiency in transferring captured viruses depends on their maturation status: mature Ͼ immature DCs, which interact with HIV via a variety of receptors, such as CD4, C-type lectin receptors (CLRs), and CCRs. Which receptors are involved depends on the DC subset and its state of maturation [16] . However, early DCs transfer to CD4 ϩ T cells is multifaceted and potentially involves one or more CLRs and other unknown pathways [16, 17] .
M⌽ and CD4 ϩ T cells are seen predominately as infectious cell (active) substrates, although both cell types retain the capacity to traffic virus independent of infection [18] . Much like DCs, M⌽ capture and internalize HIV using the CLR CD206 (mannose receptor) [19] , and this may provide another pathway through which virus is trafficked to more permissive CD4 ϩ T cells.
Virus infection of cellular substrates (active substrates; Fig. 1B )
Infection of memory CD4 ϩ T cells primarily occurs in distinct crypts of the L. propria in vivo, underscoring the major obstacle that the epithelial barrier represents to the virus [4, 6] . The abundance of such infected cell types is believed to ensure viral dissemination [6] . Memory CD4 ϩ T cells allow replication of HIV/SIV, but how these cells first "receive" the virus or get the signals to drive replication (prior to the detected, amplified virus) likely comes from local APC (DCs and M⌽).
It is unclear what role M⌽ might play during early viral transmission, yet there is evidence of low-level infection of DCs in vivo. Spira et al. [20] were the first to implicate DCs in peripheral tissues as the first targets of HIV. Later work found DCs (intraepithelial LCs) to be the first substrates of viral infection [21] . Unlike DCs carrying virus, infected, immature DCs are exquisitely potent at transferring newly produced virus, even when the level of DCs infection is below the limit of in vitro detection [22] . It is possible that similar low levels of DCs and M⌽ infection occur in vivo and largely go undetected until the virus is amplified significantly within the memory T cell pool. Moreover, the viruses produced in M⌽ [23] or DCs [24] have different characteristics to those replicating in T cells. Carrying different host molecules within the viral membrane (DC-derived), more complex glycosylation patterns (M⌽-derived), and/or higher levels of envelope (M⌽-derived) may also provide further problems for microbicide development.
Extrapolation of in vitro and the limitations of in vivo observations
Although there are many mechanisms that have been highlighted in vitro, care must be taken for their relevance and thus, final extrapolation to the in vivo setting. For instance, the mechanism of "trans" enhancement (the ability for a cell to uptake virus and transfer it to a permissive cellular recipient at an efficiency greater than the initial viral inoculum) has been demonstrated by many in various, different cellular backgrounds in vitro, especially DCs. Yet the question still remains as to whether this would be active in vivo, and currently, there is little evidence from animal and/or epidemiological studies of human transmission that it does. With respect to the logisti- cally difficult in vivo observations in animals and humans, such studies are an important "snap shot" of transmission, but sampling still remains a chronic problem. For example, the infectious crypts observed recently in macaque models highlight the importance of primary barriers and the presence of bottlenecks, but what of the events prior to this, and what is the contribution of cells of low abundance (e.g., DC), which may be lost within the thousands of tissue sections? Thus, one must carefully consider the potential of many different pathways in transmission, as current in vitro models may not be representative of key mechanisms, and in vivo sampling also has the potential to miss them.
Pathogenic modulation of cellular substrates
The presence of other sexually transmitted pathogens (e.g., Neisseria gonorrhea, Chlamydia trachomatis, HSV-2), especially those causing ulcerative lesions, dramatically increases the chances of acquiring or transmitting HIV [25, 26] . The damaged epithelial barriers and subsequent infiltration of activated leukocytes into the lesions might allow HIV to access target cells directly ( Fig. 1) [27] . The recent evidence that pathogens such as HSV-2 can paralyze DC function also suggests that dampened immune function mediated by HSV-2 might further enhance the establishment of HIV infection [28 -30] .
HIV may also directly modulate target populations (particularly DCs and T cells) [31] to support its own replication. Nef, one accessory protein of HIV/SIV, might enhance viral replication [32, 33] via several specific mechanisms, including modulation of DC-T cell contact, signaling cascades (e.g., p21-activated kinase) [34, 35] , induction of chemokine and cytokine secretion [36 -38] , and/or via other unknown direct or indirect mechanisms. Given the multifaceted nature of Nef and its potential to drive viral replication, inhibition of this key accessory protein may represent an unrecognized approach in microbicide development.
External influences on substrates
Some pathogens affect HIV transmission/infection, but they might also impact the development of AIDS. ECs and DC are able to defend against incoming pathogens by activating innate (and ultimately adaptive) immune functions; e.g., the interaction of TLRs and their pathogen-specific ligands [39] trigger specific (immune) responses [40 -42] . These signaling cascades lead to the expression of various factors involved in immune activation [43] and might influence HIV spread.
Studies in the macaque demonstrated that topical application of a TLR9 ligand slightly increased vaginal infection [44] . In contrast, ex vivo studies about lymphoid tissues from infected macaques observed a dampening of virus replication in response to TLR3 stimulation using the synthetic dsRNA analog polyinosinic:polycytidylic acid {poly(I:C)} [45] . TLR3 ligation on ECs elicits potent chemokine and cytokine responses as well as the release of bactericidal and virucidal agents at times when adaptive immunity is down-regulated by sex hormones to meet the constraints of procreation [1] . These studies propose a considerable role of the mucosal innate immune system with respect to HIV infection/transmission. We recently found that poly(I:C) treatment of HIV-loaded, immature DC impedes DC-driven infection in vitro (S. Trapp and M. Robbiani, unpublished observations). Signaling through specific TLR molecules might represent another strategy to limit sexual transmission of HIV.
CHALLENGES OF MICROBICIDE DEVELOPMENT IN LIGHT OF HIV TRANSMISSION MODELS
Given the complexities faced by the virus at the mucosa, it is surprising that the virus can establish an infectious niche. Primary barriers play a key role in complicating HIV dissemination, and one approach in microbicide development is to strengthen these existing mechanisms. A variety of strategies are being explored and are summarized herein ( Table 1 ). The potential modes of action are considered in Figure 2 .
Maintenance of the primary barriers
Mimicking the acidic, protective nature of lactobacilli is one method by which BufferGel (ReProtect, Inc., Baltimore, MD) and Acidform (TOPCAD, Chicago, IL) destroy incoming pathogens. In addition, thickening of the epithelial barrier through estrogen pretreatment is another method that proved successful in preventing SIV transmission [2] .
Disruptive agents

Surfactants
Many pathogens are dependent on their membrane integrity to maintain infectivity, and thus, viral membrane disruption represents one strategy to kill pathogens. The first surfactant unsuccessfully tested in clinical trials was N-9, which might have even promoted viral transmission by destroying physiological barriers [46] . As an alternative substance, C31G has broader activity (HSV-2 and HIV) and is in clinical trials. C31G has been effective in postcoital contraceptive activity [47] and has promising safety profiles.
Specific permeabilization of the virions-2-hydroxy-propyl-␤-cyclodextrin (␤-CD)
HIV buds selectively through areas in the plasma membrane called lipid rafts. Therefore, interrupting lipid rafts by using ␤-CD seems to be a promising tool for microbicide approaches. ␤-CD is effective in vitro [48] and in vivo at blocking cellassociated HIV transmission in the murine severe combined immunodeficiency disease (SCID) human (SCIDhu) model [49] . The advantage of this method over the broader-acting surfactants may indeed be that it specifically mediates viral lysis while maintaining mucosal epithelial integrity.
Broad-acting chemical barriers
Several sulfated, sulfonated polymers and poly-anions, including polystyrene sulfonate, napthelene sulfonate (Pro 2000), cellulose sulfate, CAP, and carrageenans derived from Red Seaweed (Carraguard) have broad, antipathogen activity [HSV, human papilloma virus, N. gonorrhea, C. trachomatis]. The action of sulfated polymers toward ϫ4 isolates blocks the HIV envelope and CXCR4 interaction [50] , although the broad activity of these compounds may be a function of pathogenic absorption to the ECs and/or other target cells through molecules such as heparan sulfate [10] (Fig. 2D) .
In vivo, the levels of compound currently used are far in excess of what is needed for blocking in in vitro studies. Thus, the gel-forming nature of large, charged polymers may also provide a primary barrier similar to mucosal secretions and may afford additional protection through lubrication and protection of the upper epithelial lining during sex ( Fig. 2A) . Macaque studies have demonstrated the potential for several of these compounds in limiting vaginal SIV infection (Table 1) [51, 52] (Carraguard; David Phillips, Population Council, New York, personal communication, and S. G. Turville and M. Robbiani, unpublished observations). The added benefit of this class of compounds is that they may serve as carriers for other antiretroviral drugs, as recently seen with the NNRTI MIV-150 formulation with Carraguard [53] . The additional activities against other sexually transmitted pathogens are also a major appeal for this sort of approach (e.g., Carraguard activity against multiple microorganisms [54 -56] ).
HIV-specific microbicides
HIV glycan
The mechanism of HIV attachment, fusion, and entry has been studied extensively, and specific compounds are now available, which act on several of these pathways. In terms of attachment, several compounds are targeted toward the glycosylation sites of the HIV envelope. CNV has the ability to inactivate virions potently and irreversibly by binding to high mannose envelope surface glycans and is effective in vitro and in vivo [57, 58] . Given DCs and M⌽ also bind HIV through mannose residues on HIV, there is likely to be an added benefit of competing ligands such as CNV. DCs are capable of internalizing virus in the presence of CNV, although virions are rendered inactive by previous exposure to these compounds [22] . 
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c Current HIV microbicides, which are routinely available for therapeutic use. CAP, Cellulose acetate 1,2-benzenedicarboxylate; N-9, nonoxynol-9; PSC-RANTES, L-Thia-Pro 2 , L-␣-cyclohexylen-gly 3 -NNY-RANTES; PMPA, 9-[2-(phosphonomethoxy)propyl]adenine; NRTI, nucleoside RT inhibitor; NNRTI, non-NRTI.
HIV envelope-CD4 interactions
The first in vivo study to look at disrupting the CD4-HIV envelope interaction at the mucosa used the neutralizing antibody b12 [59] . In a similar manner, BMS-378806 was sufficient to induce significant protection in macaques [60] . As with CNV, CD4-IgG2 (similar in action to BMS-378806) does not block virus capture by DCs but does block the subsequent spread to T cells [61] . Thus, the CD4-binding site class may afford significant protection by acting directly on incoming virions (Fig. 2B) . Even uptake of viruses bound by these agents (by ECs, DCs, or M⌽) and subsequent transfer to CD4 ϩ T cells would not thwart the blocking activity, as it is highly probable that the CD4-dependent infection of the recipient T cells would have been inactivated.
Fusion inhibitors
Linear peptides derived from the membrane region of the gp41 are effective inhibitors of a broad range of HIV isolates as a result of the conserved nature of the hydrophobic groove to which these peptides bind [62] . T-20 (enfuvirtide) is currently in clinical use as a salvage, antiretroviral therapy [63] . In macaque studies, C52L only protected 50% of animals when used at high levels, although in combinations known to be synergistic in vitro, C52L with BMS-378806 or the CCR5 inhibitor CMPD167 (or both) were more effective in macaque challenges [60] . It is difficult to establish whether this was synergistic in vivo. Given the high levels of the fusion inhibitors that are needed for topical application, others have investigated the potential of using recombinant, colonizing bacteria to secrete active fusion peptides [64] .
CCR5-based inhibitors
Individuals carrying the homozygous CCR5-⌬32 mutation do not appear to show any clinical abnormalities and are significantly resistant to HIV acquisition [65] . Thus, inhibitors toward CCR5 have been pursued for therapeutic and microbicidal applications. CMPD167 (a small CCR5-specific molecule) is capable of preventing transmission in vitro and in vivo [60] . In addition, analogs of the natural CCR5 ligand RANTES, PSC-RANTES, also demonstrated dose-dependent inhibition of infection in macaques [66] . Being able to block CCR5-dependent infection following topical application further emphasizes that the early events during HIV transmission are dependent on local infection. This seeds sites that ultimately amplify virus to reach a critical threshold and eventually spill over into the draining lymphatics to colonize the rest of the body [4] (Figs. 1 and 2D ).
RTIs
As CCR5 inhibitor observations support the importance of infection in peripheral tissue prior to further viral dissemination, then other well-characterized inhibitors of viral replication may also be effective. NRTIs and NNRTIs are currently being tested as topical microbicides in Phases I and II clinical trials, the NRTI Tenofovir, and the NNRTIs TMC-120 and UC-781 (MIV-150 in the form of PC-185 is scheduled for Phase I clinical trials; Table 1 ). To date, the only published animal studies have been conducted in the murine SCIDhu model. Naturally, there are concerns that the use of RTIs may lead to the development of resistant strains or that they might prove less effective as a result of existing RTI resistance. As TMC-120, UC-781, and MIV-150 are not used in any current therapy regimes, and as resistance is difficult to achieve in propria, but in either case, the virus is not infectious. (C) HIV-specific microbicides, which inhibit specific enzymatic activities (e.g., NNRTIs), can directly inactivate cell-free virions (inactive virions marked internally with X). In this case, contact with microbicide renders the virions inactive before or as they enter the body (similar to that described in B). (D) CCR5 inhibitors (or other HIV receptors involved in infection, e.g., CD4, CXCR4) block the capacity for virus to infect permissive targets (represented in the figure by "X"). These agents likely diffuse into the tissues to limit infection by virus, which penetrates into the L. propria to access the most permissive cells. This prevents the establishment of an infectious seeding site to allow for further dissemination. act-T, Activated CD4 ϩ T cells of the L. propria.
vitro, this might not become reality. In addition, the ability for NNRTIs to cross virus membranes and irreversibly inactivate virions makes them attractive candidates, as they act directly on cell-free virions (Fig. 2C) .
The potential problems with monomicrobicides: the concern of resistance Current microbicide formulations, especially those in clinical trials, all consist of one active, antiviral component. Most of these antivirals/microbicides are not being used in therapy to date (with the exception of Tenofovir), although many are being developed in parallel with future therapeutics (e.g., CCR5-based compounds and fusion inhibitors). The coadministration of compounds in therapeutics and as microbicides within a population does raise concerns of an increasing number of resistant strains being transmitted over time. Resistance to related compounds, which are currently in antiretroviral therapy, may also impact on those currently being used as microbicides. For example, resistance to the NNRTI Efavirenz (currently in therapy) has a significant impact on the potency of the NNRTI UC781 as a microbicide [67] . Although NNRTIs are used as an example herein, the same may apply to any singlebased microbicide, where there is potential for resistance. As highlighted above, the dual use of compounds in therapeutics/ microbicide strategies may indeed accelerate the existence of circulating, resistant strains in a given population, but there still may be the potential for resistance to microbicides, which are designated solely for microbicide use.
Combinations
Given the concerns of resistant viral isolates arising from single, compound-based microbicides, the support for multiple combination strategies is growing. Indeed, when synergistic combinations are found, the level of compound theoretically needed is reduced, and the benefit of this is clear in terms of mucosal bioavailability and cost of production. Currently, the only combination microbicide scheduled for clinical trials is PC-815 (carrageenan and MIV-150 combination, Table 1 ). We recently confirmed that PC-815 could protect animals against vaginal simian human immunodeficiency virus-RT challenge (S. G. Turville and M. Robbiani, unpublished). Using other products in combination, macaque studies provide encouraging evidence that synergistic combinations found in vitro do provide good protection in vivo [60] , although the licensing of new microbicides, in addition to potential competition between microbicide developers/manufacturers, may influence and potentially restrict future combinations and therefore, may not be equivalent to the therapeutic situation of combination antiretroviral therapy. The latter situation can be resolved with collaboration or release of licenses for open microbicide use, and precedent for such has recently taken place [68] and thus, may encourage others to do so.
CONCLUSION
HIV transmission in vivo is multifactorial, and it remains unclear as to which cells are first targeted by HIV to establish infection and facilitate dissemination. It is likely an orchestrated series of events involving multiple cell types, which eventually result in the robust infection of memory CD4 ϩ T cells. The virus will not likely have to infect all of the cells it encounters (ECs, DCs, and M⌽) but will exploit traffic through these cells to be ferried rapidly to the more permissive targets (low-level infection of DCs/M⌽ and vigorous replication in CD4 ϩ T cells). Thus, how to address these complex pathways in microbicide design becomes somewhat daunting. Microbicides, which are in clinical trials, have taken a broad approach to block several incoming pathogens. One common feature of the broad inhibitors is to strengthen existing primary barriers (e.g., pH regulation, estrogen treatment, additional absorption barrier with sulfated polymers). Inhibitors specifically inactivating the incoming viruses (e.g., CNV, BMS-378806, NNRTIs) also hold promise. Agents working at the level of the cell are also yielding surprising and effective results in animal microbicide studies (e.g., CCR5 inhibitors). However, the future of microbicides may lie in combinations, which impair the virus at multiple levels. For instance, a combination, which encourages the strength of the vaginal barrier in addition to specific HIV targeting, may not only provide two lines of defense against HIV but also may hinder the acquisition of other sexually transmitted pathogens associated with increasing HIV infection. Whether a microbicide is in combination with another or in isolation, knowing that putative formulations function in the face of (or even protect against) other pathogens is critical for their success.
